<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD00740000_1</Organism_ID>
  <Organism>Chicken</Organism>
  <Organism_Latin>Gallus gallus</Organism_Latin>
  <UniProt_ID>P00523</UniProt_ID>
  <Seq_Length>533</Seq_Length>
  <Molecule_Weight>60010</Molecule_Weight>
  <KEGG_ID>gga:396442</KEGG_ID>
  <Orthology_ID>K05704</Orthology_ID>
  <EBI_ID>EBI-848039</EBI_ID>
  <Function_Summary>Non-receptor protein tyrosine kinase which is activated following engagement of many different classes of cellular receptors including immune response receptors, integrins and other adhesion receptors, receptor protein tyrosine kinases, G protein-coupled receptors as well as cytokine receptors. Participates in signaling pathways that control a diverse spectrum of biological activities including gene transcription, immune response, cell adhesion, cell cycle progression, apoptosis, migration, and transformation. Due to functional redundancy between members of the SRC kinase family, identification of the specific role of each SRC kinase is very difficult. SRC appears to be one of the primary kinases activated following engagement of receptors and plays a role in the activation of other protein tyrosine kinase (PTK) families. Receptor clustering or dimerization leads to recruitment of SRC to the receptor complexes where it phosphorylates the tyrosine residues within the receptor cytoplasmic domains. Plays an important role in the regulation of cytoskeletal organization through phosphorylation of specific substrates involved in this process. When cells adhere via focal adhesions to the extra-cellular matrix, signals are transmitted by integrins into the cell and result in tyrosine phosphorylation of a number of focal adhesion proteins, including PTK2/FAK1 and paxillin (PXN). Also active at the sites of cell-cell contact adherens junctions and at gap junctions. Implicated in the regulation of pre-mRNA-processing. Might be involved not only in mediating the transduction of mitogenic signals at the level of the plasma membrane but also in controlling progression through the cell cycle via interaction with regulatory proteins in the nucleus.</Function_Summary>
  <Catalytic_Mechanism>ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.</Catalytic_Mechanism>
  <Pfam_ID>PF07714:Pkinase_Tyr@@PF00017:SH2@@PF00018:SH3_1</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>24</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>CSrc</Alias>
      <Alias>Pp60c-src</Alias>
      <Alias>P60-Src</Alias>
      <Alias>Proto-oncogene c-Src</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.</Detail>
      <Keyword>ATP binding</Keyword>
      <Ontology_ID>GO:0005524</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the transfer of a phosphate group, usually from ATP, to a substrate molecule.</Detail>
      <Keyword>Kinase activity</Keyword>
      <Ontology_ID>GO:0016301</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reaction: ATP + a protein tyrosine = ADP + protein tyrosine phosphate.</Detail>
      <Keyword>Protein tyrosine kinase activity</Keyword>
      <Ontology_ID>GO:0004713</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with heme, any compound of iron complexed in a porphyrin (tetrapyrrole) ring.</Detail>
      <Keyword>Heme binding</Keyword>
      <Ontology_ID>GO:0020037</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the transfer of a group, e.g. a methyl group, glycosyl group, acyl group, phosphorus-containing, or other groups, from one compound (generally regarded as the donor) to another compound (generally regarded as the acceptor). Transferase is the systematic name for any enzyme of EC class 2.</Detail>
      <Keyword>Transferase activity</Keyword>
      <Ontology_ID>GO:0016740</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a nucleotide, any compound consisting of a nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the ribose or deoxyribose.</Detail>
      <Keyword>Nucleotide binding</Keyword>
      <Ontology_ID>GO:0000166</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reaction: ATP + a non-membrane spanning protein L-tyrosine = ADP + a non-membrane spanning protein L-tyrosine phosphate.</Detail>
      <Keyword>Non-membrane spanning protein tyrosine kinase activity</Keyword>
      <Ontology_ID>GO:0004715</Ontology_ID>
    </Funtion>
  </Function_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>The progression of biochemical and morphological phases and events that occur in a cell during successive cell replication or nuclear replication events. Canonically, the cell cycle comprises the replication and segregation of genetic material followed by the division of the cell, but in endocycles or syncytial cells nuclear replication or nuclear division may not be followed by cell division.</Detail>
      <Keyword>Cell cycle</Keyword>
      <Ontology_ID>GO:0007049</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Protein involved in immunity, any immune system process that functions in the response of an organism to a potential internal or invasive threat. The vertebrate immune system is formed by the innate immune system (composed of phagocytes, complement, antimicrobial peptides, etc) and by the adaptive immune system which consists of T- and B-lymphocytes.</Detail>
      <Keyword>Immunity</Keyword>
      <Ontology_ID>KW-0391</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The attachment of a cell, either to another cell or to an underlying substrate such as the extracellular matrix, via cell adhesion molecules.</Detail>
      <Keyword>Cell adhesion</Keyword>
      <Ontology_ID>GO:0007155</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>34</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>72</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>46</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>498</Position>
      <PTM_Type>S-nitrosocysteine</PTM_Type>
    </PTM>
    <PTM>
      <Position>527</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>416</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>12</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>436</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MGSSKSKPKDPSQRRRSLEPPDSTHHGGFPASQTPNKTAAPDTHRTPSRSFGTVATEPKLFGGFNTSDTVTSPQRAGALAGGVTTFVALYDYESRTETDLSFKKGERLQIVNNTEGDWWLAHSLTTGQTGYIPSNYVAPSDSIQAEEWYFGKITRRESERLLLNPENPRGTFLVRESETTKGAYCLSVSDFDNAKGLNVKHYKIRKLDSGGFYITSRTQFSSLQQLVAYYSKHADGLCHRLTNVCPTSKPQTQGLAKDAWEIPRESLRLEVKLGQGCFGEVWMGTWNGTTRVAIKTLKPGTMSPEAFLQEAQVMKKLRHEKLVQLYAVVSEEPIYIVTEYMSKGSLLDFLKGEMGKYLRLPQLVDMAAQIASGMAYVERMNYVHRDLRAANILVGENLVCKVADFGLARLIEDNEYTARQGAKFPIKWTAPEAALYGRFTIKSDVWSFGILLTELTTKGRVPYPGMVNREVLDQVERGYRMPCPPECPESLHDLMCQCWRKDPEERPTFEYLQAFLEDYFTSTEPQYQPGENL</Protein_Seq>
    <DNA_Seq>GAATTCCTTTCTGCAGCTGTCCTGGAAGTGGAAGAGTTTGCTTCAGGAATGGGGAACTGAAATGCACGGCTTCGCTCTCCTCTCCTGAGGCCGCTCAGAACGTGAGAATTAGCAGAGAGCCCACAGGTGGTCACTGTGTGTTGGGGCGGTATTGAGAAGTGTCTTTTGGGGAGCAGGAGGGCACGTTGCCCCGGTGCTGGCCCTGCTCCACATCAGCGCTTCCCGACCCCACAGACACCAGGGCACGGGGCAGCACTCCCTCTGTTTGCTGGGCTGGGCAGGAGAGCCGTGCCCTCATCGCCTGTCTGGGAGCGGCACGCTGCGGGTTAATGCACACCAAGGGCTTTGTGCGTGTTTGGGTACTGATTGGCACTGGGCTGGCAGTCTGTGTGTGCAAACAGCGAGCTCGGGGTGGGTTTGCAGGACTCGTGCTTGTTCCATGTGCAGCTGGGGGAGCCCCAATTTAGGTGCCCTGGAGGAGGTTCAGTGGTTCTGCAGTTCTTGACCAGATGAACATCCATAACTCATGCCTGTGCTGCTCGGGGTTTGCTCTGCTCTTTGCAGCTCCTGTTTCGACACGTCTTTTTGGAGGCGTTCTGCATTGCTACCAAATGTGACTCCCCTGTGCTCGGGGGGGTGAATTTGGATGGTTCATTTAATTATCCTTTGCCTTTTCGTGACCCACCGGCCTCTGCCAGGTTGGGCTGTGAGGCTTTAATTAAGATGTCTTTCAATGTAACAGGAGTTGATGGAGTGGGATGGGAGCGGCCGCGCATTGCTTCTGCTGGGAGCACACAGCTGCACCTTACAGGGCCGTGGCGAAGGCATGGATTTGTCCTGGGGAGGGATGGAGGGATGGGCAGGGATGTGCTGGGAGGTGCCTTTGGGATGCCATCCCTGGGTGAAGCGGGGGTCCCAGGGGCAGCCGCTCCCGTGCTGTGTGAGTTGATGATAAAGTGTGGTTTGGTGCTGCTGCAGTGCCCTACGAGGTGCTCGCGTTGCAGGATCCATCCCAGCAGCCCCGTAGTGAGCAAACATCTCAGCAGCATTCCTAGCACCACCTGTCCGTGTAGGGGCACACACCGATGTGCAGAGCAGGGCTGTGCCGTGCCGTGCCCTGCTGGCAGCTGCCATCACCCCGTGCTGCTGCGTGACCCTCCCGCGTGCTCTGTGCCTCACACCAGCCCATCCCCACTCCCATCCATAGGGATGCCTGCTGTGCACAAGGACTTGGGGCTGCACTCCCGCCCTGTTCTGCTGTCCCTGGTTCCATGGGCTCAGCTCTGCACCGCACCGTGGCTTTGTCTGCCCAGCGCGCTGCCTGCTCCATTTGTCAGTCTGGCAGCAGACAGGTGCAGTCATTCATCGTGCTGTGCTGTGTGAGCTGATGGAGCACGGGGGGAAACCTTGGCCTGTGCTGGCCCCTCGTCCCACTGCTTATATCCAAAAGGATGCTCTCGGTTTTCTATGCTACAAACCAGGCTGGGGTTAACGCGCGGCTCTTCCAGGCAGGGCTGGCGGAGGCTGTGCTGCAGGGAAGGGAAGAAATACAGAGTTGAGGGGGGATTTAAAGCTGGTGGCGAGGCACTGCGTGGTGTCCCCGTGCCAATCTCCCTTCCTGCCGACTGCAGTGTCCTGGAGCACTGTCCCATCCCGCCTGCTCGGCGCCCACCCAGCAGCCCAAGGACGCGGTATGTCAGCAGATCTGTTCCCCCCCCCCCAAGGCTCACTGTCTGGCTGGGCCCCAGCATGTCGCAGATCCTCCCAAGGTCTCTGCTTCTGCCGCACAGAAGGCAGCGAAATGTGGAATTTCTGTGTTTCGTCTGCTCCCAATCAGTGCCTTTTGTTGGTGTCTTTGAGAGGGGGGGGGGGAAAAAACAAAGAAATAAGATAAGCTCGTGTCCTCCCCCCCCCCCCCCATACTGCCAGCCCTGCTGTCGGCGTGGCTCTTACAACTCCCATTGTATCCTTGAGCCGCCCGGCGCAGCACACAGCCTGTCTGCAGGAGACGGATGACCCTGAGCGGCCGCTTCCCCCGGCGCTGCTTTCCCACAGCATCCCTGCAAGGAGCTGAGCTGACTCTGCTGGTGGCCTCGCGTACCACTGTGGCCAGGCGGTAGCTGGGACGTGCAGCCCACCACCATGGGGAGCAGCAAGAGCAAGCCCAAGGACCCCAGCCAGCGCCGGCGCAGCCTGGAGCCACCCGACAGCACCCACCACGGGGGATTCCCAGCCTCGCAGACCCCCAACAAGACAGCAGCCCCCGACACGCACCGCACCCCCAGCCGCTCCTTTGGGACCGTGGCCACCGAGCCCAAGCTCTTCGGGGGCTTCAACACTTCTGACACCGTCACGTCGCCGCAGCGTGCCGGGGCACTGGCTGGCGGCGTCACCACTTTCGTGGCTCTCTACGACTACGAGTCCCGGACTGAAACGGACTTGTCCTTCAAGAAAGGAGAACGCCTGCAGATTGTCAACAACACGGAAGGTGACTGGTGGCTGGCTCATTCCCTCACTACAGGACAGACGGGCTACATCCCCAGTAACTATGTCGCGCCCTCAGACTCCATCCAGGCTGAAGAGTGGTACTTTGGGAAGATCACTCGTCGGGAGTCCGAGCGGCTGCTGCTCAACCCCGAAAACCCCCGGGGAACCTTCTTGGTCCGGGAGAGCGAGACGACAAAAGGTGATCCCTGCATACCCCTTCCCTCATGCCTCTGCTAGAGCCACGATGCTGGGAGCAGCCTGCAGGGGTCCTCCAGCACTTGGTCACCACGTGGTCCCAATCCCCCTGACCAAGGTGTACCGAAGAGATGAGCCTCCTGCACTGCGTTCACCCCCAGTTTCTCCCACGTTTTGCTTTCATAGATGTCCCCTTCACACTCTGTTCTTGTCCCATTGCCCAAGCTGGAGGCAGAGATGGTCCCATGCACGACATCCCGGTTTTACCCTCTAATGGTTTCCCCACTGATGTGCCCACATAACTCCGAAGGGTTGGGAACAACACCATATCCTCTCCTGGGCTTTTCTGTGCGTTCTTTTTGTCCCCGGGCACATGAGTTTTGTGGAATTCC</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Widely expressed</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytoplasm</CellLocal>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>SRC</Gene_Name>
    <Gene_ID>396442</Gene_ID>
    <Genbank_ACCN>NM_205457</Genbank_ACCN>
    <Protein_ACCN>NP_990788</Protein_ACCN>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/396442</Gene_URL>
    <EMBL_ID>ENSGALG00000003855</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>P41240</Uniprot_ID>
      <Gene_Name>CSK</Gene_Name>
      <EBI_ID>EBI-1380630</EBI_ID>
      <PPI_EBI_URL>EBI-848039,EBI-1380630</PPI_EBI_URL>
      <Experiment_Number>6</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q9QWY8-2</Uniprot_ID>
      <Gene_Name>Asap1</Gene_Name>
      <EBI_ID>EBI-698524</EBI_ID>
      <PPI_EBI_URL>EBI-848039,EBI-698524</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q9QWI6-2</Uniprot_ID>
      <Gene_Name>Srcin1</Gene_Name>
      <EBI_ID>EBI-775607</EBI_ID>
      <PPI_EBI_URL>EBI-848039,EBI-775607</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q9QWY8-1</Uniprot_ID>
      <Gene_Name>Asap1</Gene_Name>
      <EBI_ID>EBI-698517</EBI_ID>
      <PPI_EBI_URL>EBI-848039,EBI-698517</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
  </PPI_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Kinase domain of cSrc in complex with RL103</PDB_Title>
      <PDB_ID>3TZ7</PDB_ID>
      <Resolution>3.3</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3TZ7</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD00740027</ASD_Ligand>
      <PubMed_Title>Overcoming Gatekeeper Mutations in cSrc and Abl by Hybrid Compound Design</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the c-src-SH3 domain</PDB_Title>
      <PDB_ID>3FJ5</PDB_ID>
      <Resolution>1.65</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FJ5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Intertwined dimeric structure for the SH3 domain of the c-Src tyrosine kinase induced by polyethylene glycol binding</PubMed_Title>
      <Author>Camara-Artigas A, et al.</Author>
      <Journal>FEBS Lett. 2009 Feb 18;583(4):749-53.</Journal>
      <PubMed_ID>19185573</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Targeted polypharmacology: crystal structure of the c-Src kinase domain in complex with PP102, a multitargeted kinase inhibitor</PDB_Title>
      <PDB_ID>3EN6</PDB_ID>
      <Resolution>2.39</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3EN6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.</PubMed_Title>
      <Author>Apsel B, et al.</Author>
      <Journal>Nat Chem Biol. 2008 Nov;4(11):691-9.</Journal>
      <PubMed_ID>18849971</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>1H AND 15N ASSIGNMENTS AND SECONDARY STRUCTURE OF THE SRC SH3 DOMAIN</PDB_Title>
      <PDB_ID>1SRM</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1SRM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>1H and 15N assignments and secondary structure of the Src SH3 domain.</PubMed_Title>
      <Author>Yu H, et al.</Author>
      <Journal>FEBS Lett. 1993 Jun 7;324(1):87-92.</Journal>
      <PubMed_ID>8504863</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>SRC SH2 THREF1TRP MUTANT</PDB_Title>
      <PDB_ID>1F2F</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1F2F</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for specificity switching of the Src SH2 domain.</PubMed_Title>
      <Author>Kimber MS, et al.</Author>
      <Journal>Mol Cell. 2000 Jun;5(6):1043-9.</Journal>
      <PubMed_ID>10911998</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CHICKEN SRC TYROSINE KINASE</PDB_Title>
      <PDB_ID>2PTK</PDB_ID>
      <Resolution>2.35</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PTK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The 2.35 A crystal structure of the inactivated form of chicken Src: a dynamic molecule with multiple regulatory interactions.</PubMed_Title>
      <Author>Williams JC, et al.</Author>
      <Journal>J Mol Biol. 1997 Dec 19;274(5):757-75.</Journal>
      <PubMed_ID>9405157</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of c-Src in complex with pyrazolopyrimidine 3</PDB_Title>
      <PDB_ID>3EL7</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3EL7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Small Molecule Recognition of c-Src via the Imatinib-Binding Conformation</PubMed_Title>
      <Author>Dar AC, et al.</Author>
      <Journal>(2008) Chem.Biol. 15: 1015-1022</Journal>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of drug resistant SRC kinase domain with irreversible inhibitor</PDB_Title>
      <PDB_ID>2QQ7</PDB_ID>
      <Resolution>2.38</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2QQ7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR.</PubMed_Title>
      <Author>Michalczyk A, et al.</Author>
      <Journal>Bioorg Med Chem. 2008 Apr 1;16(7):3482-8.</Journal>
      <PubMed_ID>18316192</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations</PDB_Title>
      <PDB_ID>3G6G</PDB_ID>
      <Resolution>2.31</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3G6G</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD00740024</ASD_Ligand>
      <PubMed_Title>Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations.</PubMed_Title>
      <Author>Seeliger MA, et al.</Author>
      <Journal>Cancer Res. 2009 Mar 15;69(6):2384-92.</Journal>
      <PubMed_ID>19276351</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of Src kinase domain in complex with covalent inhibitor PD168393</PDB_Title>
      <PDB_ID>2HWP</PDB_ID>
      <Resolution>2.48</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2HWP</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure-guided development of affinity probes for tyrosine kinases using chemical genetics.</PubMed_Title>
      <Author>Blair JA, et al.</Author>
      <Journal>Nat Chem Biol. 2007 Apr;3(4):229-38.</Journal>
      <PubMed_ID>17334377</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of c-Src in complex with pyrazolopyrimidine 5</PDB_Title>
      <PDB_ID>3EL8</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3EL8</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD09800002</ASD_Ligand>
      <PubMed_Title>Small Molecule Recognition of c-Src via the Imatinib-Binding Conformation</PubMed_Title>
      <Author>Dar AC, et al.</Author>
      <Journal>(2008) Chem.Biol. 15: 1015-1022</Journal>
    </PDB>
    <PDB>
      <PDB_Title>c-Src kinase domain in complex with small molecule inhibitor</PDB_Title>
      <PDB_ID>3F6X</PDB_ID>
      <Resolution>2.35</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3F6X</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Tuning a three-component reaction for trapping kinase substrate complexes.</PubMed_Title>
      <Author>Statsuk AV, et al.</Author>
      <Journal>J Am Chem Soc. 2008 Dec 24;130(51):17568-74.</Journal>
      <PubMed_ID>19053485</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Discovery of a small molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases</PDB_Title>
      <PDB_ID>4AGW</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4AGW</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD00740025</ASD_Ligand>
      <PubMed_Title>Discovery of a Small-Molecule Type II Inhibitor of Wild-Type and Gatekeeper Mutants of Bcr-Abl, Pdgfralpha, Kit, and Src Kinases: Novel Type II Inhibitor of Gatekeeper Mutants.</PubMed_Title>
      <Author>Weisberg, E., et al.</Author>
      <Journal>Blood(2010)115:4206</Journal>
      <PubMed_ID>20299508</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Kinase domain of cSrc in complex with inhibitor RL45 (Type II)</PDB_Title>
      <PDB_ID>3F3V</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3F3V</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD00740016</ASD_Ligand>
      <PubMed_Title>Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc.</PubMed_Title>
      <Author>Getlik M, et al.</Author>
      <Journal>J Med Chem. 2009 Jul 9;52(13):3915-26.</Journal>
      <PubMed_ID>19462975</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Targeted polypharmacology: crystal structure of the c-Src kinase domain in complex with S1, a multitargeted kinase inhibitor</PDB_Title>
      <PDB_ID>3EN7</PDB_ID>
      <Resolution>2.81</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3EN7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.</PubMed_Title>
      <Author>Apsel B, et al.</Author>
      <Journal>Nat Chem Biol. 2008 Nov;4(11):691-9.</Journal>
      <PubMed_ID>18849971</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Drug resistant cSrc kinase domain in complex with inhibitor RL45 (Type II)</PDB_Title>
      <PDB_ID>3F3W</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3F3W</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD00740016</ASD_Ligand>
      <PubMed_Title>Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc.</PubMed_Title>
      <Author>Getlik M, et al.</Author>
      <Journal>J Med Chem. 2009 Jul 9;52(13):3915-26.</Journal>
      <PubMed_ID>19462975</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of drug resistant SRC kinase domain</PDB_Title>
      <PDB_ID>2QI8</PDB_ID>
      <Resolution>2.32</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2QI8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR.</PubMed_Title>
      <Author>Michalczyk A, et al.</Author>
      <Journal>Bioorg Med Chem. 2008 Apr 1;16(7):3482-8.</Journal>
      <PubMed_ID>18316192</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Kinase domain of cSrc in complex with inhibitor RL38 (Type III)</PDB_Title>
      <PDB_ID>3F3T</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3F3T</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD00740003</ASD_Ligand>
      <PubMed_Title>A new screening assay for allosteric inhibitors of cSrc.</PubMed_Title>
      <Author>Simard JR, et al.</Author>
      <Journal>Nat Chem Biol. 2009 Jun;5(6):394-6.</Journal>
      <PubMed_ID>19396179</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Src SH2 Domain Complexed with Peptide (SDpYANFK)</PDB_Title>
      <PDB_ID>1P13</PDB_ID>
      <Resolution>1.63</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1P13</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The structure of the membrane distal phosphatase domain of RPTPalpha reveals interdomain flexibility and an SH2 domain interaction region.</PubMed_Title>
      <Author>Sonnenburg ED, et al.</Author>
      <Journal>Biochemistry. 2003 Jul 8;42(26):7904-14.</Journal>
      <PubMed_ID>12834342</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Targeted polypharmacology: crystal structure of the c-Src kinase domain in complex with PP121, a multitargeted kinase inhibitor</PDB_Title>
      <PDB_ID>3EN4</PDB_ID>
      <Resolution>2.55</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3EN4</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.</PubMed_Title>
      <Author>Apsel B, et al.</Author>
      <Journal>Nat Chem Biol. 2008 Nov;4(11):691-9.</Journal>
      <PubMed_ID>18849971</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Kinase domain of cSrc in complex with RL130</PDB_Title>
      <PDB_ID>3TZ9</PDB_ID>
      <Resolution>3.1</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3TZ9</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD00740028</ASD_Ligand>
      <PubMed_Title>Overcoming Gatekeeper Mutations in cSrc and Abl by Hybrid Compound Design</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>c-Src kinase domain Thr338Ile mutant in complex with ATPgS</PDB_Title>
      <PDB_ID>3DQW</PDB_ID>
      <Resolution>2.02</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3DQW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Activation of tyrosine kinases by mutation of the gatekeeper threonine.</PubMed_Title>
      <Author>Azam M, et al.</Author>
      <Journal>Nat Struct Mol Biol. 2008 Oct;15(10):1109-18.</Journal>
      <PubMed_ID>18794843</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Kinase domain of cSrc in complex with RL104</PDB_Title>
      <PDB_ID>3TZ8</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3TZ8</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD00740029</ASD_Ligand>
      <PubMed_Title>Overcoming Gatekeeper Mutations in cSrc and Abl by Hybrid Compound Design</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>TWO BINDING ORIENTATIONS FOR PEPTIDES TO SRC SH3 DOMAIN: DEVELOPMENT OF A GENERAL MODEL FOR SH3-LIGAND INTERACTIONS</PDB_Title>
      <PDB_ID>1RLP</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1RLP</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Two binding orientations for peptides to the Src SH3 domain: development of a general model for SH3-ligand interactions.</PubMed_Title>
      <Author>Feng S, et al.</Author>
      <Journal>Science. 1994 Nov 18;266(5188):1241-7.</Journal>
      <PubMed_ID>7526465</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Kinase domain of cSrc in complex with Dasatinib</PDB_Title>
      <PDB_ID>3G5D</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3G5D</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD00740011</ASD_Ligand>
      <PubMed_Title>Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc.</PubMed_Title>
      <Author>Getlik M, et al.</Author>
      <Journal>J Med Chem. 2009 Jul 9;52(13):3915-26.</Journal>
      <PubMed_ID>19462975</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>TWO BINDING ORIENTATIONS FOR PEPTIDES TO SRC SH3 DOMAIN: DEVELOPMENT OF A GENERAL MODEL FOR SH3-LIGAND INTERACTIONS</PDB_Title>
      <PDB_ID>1PRL</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1PRL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Two binding orientations for peptides to the Src SH3 domain: development of a general model for SH3-ligand interactions.</PubMed_Title>
      <Author>Feng S, et al.</Author>
      <Journal>Science. 1994 Nov 18;266(5188):1241-7.</Journal>
      <PubMed_ID>7526465</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of SRC kinase domain with covalent inhibitor RL3</PDB_Title>
      <PDB_ID>2QLQ</PDB_ID>
      <Resolution>2.33</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2QLQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR.</PubMed_Title>
      <Author>Michalczyk A, et al.</Author>
      <Journal>Bioorg Med Chem. 2008 Apr 1;16(7):3482-8.</Journal>
      <PubMed_ID>18316192</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of chicken c-Src kinase domain in complex with the cancer drug imatinib.</PDB_Title>
      <PDB_ID>2OIQ</PDB_ID>
      <Resolution>2.07</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2OIQ</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD00740007</ASD_Ligand>
      <PubMed_Title>c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty.</PubMed_Title>
      <Author>Seeliger MA, et al.</Author>
      <Journal>Structure. 2007 Mar;15(3):299-311.</Journal>
      <PubMed_ID>17355866</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Kinase domain of cSrc in complex with inhibitor RL37 (Type III)</PDB_Title>
      <PDB_ID>3F3U</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3F3U</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD00740002</ASD_Ligand>
      <PubMed_Title>A new screening assay for allosteric inhibitors of cSrc.</PubMed_Title>
      <Author>Simard JR, et al.</Author>
      <Journal>Nat Chem Biol. 2009 Jun;5(6):394-6.</Journal>
      <PubMed_ID>19396179</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>chicken c-Src kinase domain in complex with ATPg</PDB_Title>
      <PDB_ID>3DQX</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3DQX</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Activation of tyrosine kinases by mutation of the gatekeeper threonine.</PubMed_Title>
      <Author>Azam M, et al.</Author>
      <Journal>Nat Struct Mol Biol. 2008 Oct;15(10):1109-18.</Journal>
      <PubMed_ID>18794843</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structural basis for the chemical rescue of Src kinase activity</PDB_Title>
      <PDB_ID>3GEQ</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3GEQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Comparative analysis of mutant tyrosine kinase chemical rescue.</PubMed_Title>
      <Author>Muratore KE, et al.</Author>
      <Journal>Biochemistry. 2009 Apr 21;48(15):3378-86.</Journal>
      <PubMed_ID>19260709</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>TWO BINDING ORIENTATIONS FOR PEPTIDES TO SRC SH3 DOMAIN: DEVELOPMENT OF A GENERAL MODEL FOR SH3-LIGAND INTERACTIONS</PDB_Title>
      <PDB_ID>1RLQ</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1RLQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Two binding orientations for peptides to the Src SH3 domain: development of a general model for SH3-ligand interactions.</PubMed_Title>
      <Author>Feng S, et al.</Author>
      <Journal>Science. 1994 Nov 18;266(5188):1241-7.</Journal>
      <PubMed_ID>7526465</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>SRC SH2 THREF1TRP MUTANT COMPLEXED WITH THE PHOSPHOPEPTIDE S(PTR)VNVQN</PDB_Title>
      <PDB_ID>1F1W</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1F1W</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for specificity switching of the Src SH2 domain.</PubMed_Title>
      <Author>Kimber MS, et al.</Author>
      <Journal>Mol Cell. 2000 Jun;5(6):1043-9.</Journal>
      <PubMed_ID>10911998</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Targeted polypharmacology: crystal structure of the c-Src kinase domain in complex with PP494, a multitargeted kinase inhibitor</PDB_Title>
      <PDB_ID>3EN5</PDB_ID>
      <Resolution>2.66</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3EN5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.</PubMed_Title>
      <Author>Apsel B, et al.</Author>
      <Journal>Nat Chem Biol. 2008 Nov;4(11):691-9.</Journal>
      <PubMed_ID>18849971</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Src Thr338Ile inhibited in the DFG-Asp-Out conformation</PDB_Title>
      <PDB_ID>3G6H</PDB_ID>
      <Resolution>2.35</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3G6H</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations.</PubMed_Title>
      <Author>Seeliger MA, et al.</Author>
      <Journal>Cancer Res. 2009 Mar 15;69(6):2384-92.</Journal>
      <PubMed_ID>19276351</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>TWO BINDING ORIENTATIONS FOR PEPTIDES TO SRC SH3 DOMAIN: DEVELOPMENT OF A GENERAL MODEL FOR SH3-LIGAND INTERACTIONS</PDB_Title>
      <PDB_ID>1PRM</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1PRM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Two binding orientations for peptides to the Src SH3 domain: development of a general model for SH3-ligand interactions.</PubMed_Title>
      <Author>Feng S, et al.</Author>
      <Journal>Science. 1994 Nov 18;266(5188):1241-7.</Journal>
      <PubMed_ID>7526465</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of Src kinase domain in complex with covalent inhibitor</PDB_Title>
      <PDB_ID>2HWO</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2HWO</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure-guided development of affinity probes for tyrosine kinases using chemical genetics.</PubMed_Title>
      <Author>Blair JA, et al.</Author>
      <Journal>Nat Chem Biol. 2007 Apr;3(4):229-38.</Journal>
      <PubMed_ID>17334377</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structural basis for the recognition of c-Src by its inactivator Csk</PDB_Title>
      <PDB_ID>3D7U</PDB_ID>
      <Resolution>4.11</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3D7U</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for the recognition of c-Src by its inactivator Csk.</PubMed_Title>
      <Author>Levinson NM, et al.</Author>
      <Journal>Cell. 2008 Jul 11;134(1):124-34.</Journal>
      <PubMed_ID>18614016</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structural basis for the recognition of c-Src by its inactivator Csk</PDB_Title>
      <PDB_ID>3D7T</PDB_ID>
      <Resolution>2.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3D7T</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for the recognition of c-Src by its inactivator Csk.</PubMed_Title>
      <Author>Levinson NM, et al.</Author>
      <Journal>Cell. 2008 Jul 11;134(1):124-34.</Journal>
      <PubMed_ID>18614016</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>1H AND 15N ASSIGNMENTS AND SECONDARY STRUCTURE OF THE SRC SH3 DOMAIN</PDB_Title>
      <PDB_ID>1SRL</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1SRL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>1H and 15N assignments and secondary structure of the Src SH3 domain.</PubMed_Title>
      <Author>Yu H, et al.</Author>
      <Journal>FEBS Lett. 1993 Jun 7;324(1):87-92.</Journal>
      <PubMed_ID>8504863</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04919</Pathway_ID>
      <Pathway_Title>Thyroid hormone signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05100</Pathway_ID>
      <Pathway_Title>Bacterial invasion of epithelial cells</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05161</Pathway_ID>
      <Pathway_Title>Hepatitis B</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04611</Pathway_ID>
      <Pathway_Title>Platelet activation</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05203</Pathway_ID>
      <Pathway_Title>Viral carcinogenesis</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04917</Pathway_ID>
      <Pathway_Title>Prolactin signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04520</Pathway_ID>
      <Pathway_Title>Adherens junction</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cellular commiunity</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04915</Pathway_ID>
      <Pathway_Title>Estrogen signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04062</Pathway_ID>
      <Pathway_Title>Chemokine signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04727</Pathway_ID>
      <Pathway_Title>GABAergic synapse</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Nervous system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04810</Pathway_ID>
      <Pathway_Title>Regulation of actin cytoskeleton</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cell motility</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04520</Pathway_ID>
      <Pathway_Title>Adherens junction</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cellular commiunity</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04750</Pathway_ID>
      <Pathway_Title>Inflammatory mediator regulation of TRP channels</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Sensory system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04917</Pathway_ID>
      <Pathway_Title>Prolactin signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04510</Pathway_ID>
      <Pathway_Title>Focal adhesion</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cellular commiunity</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05131</Pathway_ID>
      <Pathway_Title>Shigellosis</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04915</Pathway_ID>
      <Pathway_Title>Estrogen signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05205</Pathway_ID>
      <Pathway_Title>Proteoglycans in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05120</Pathway_ID>
      <Pathway_Title>Epithelial cell signaling in Helicobacter pylori infection</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04912</Pathway_ID>
      <Pathway_Title>GnRH signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04921</Pathway_ID>
      <Pathway_Title>Oxytocin signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04015</Pathway_ID>
      <Pathway_Title>Rap1 signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04540</Pathway_ID>
      <Pathway_Title>Gap junction</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cellular commiunity</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05205</Pathway_ID>
      <Pathway_Title>Proteoglycans in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05152</Pathway_ID>
      <Pathway_Title>Tuberculosis</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04530</Pathway_ID>
      <Pathway_Title>Tight junction</Pathway_Title>
      <Pathway_Class>Cellular Processes</Pathway_Class>
      <Pathway_Subclass>Cellular commiunity</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04370</Pathway_ID>
      <Pathway_Title>VEGF signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04012</Pathway_ID>
      <Pathway_Title>ErbB signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>Alpha and beta proteins (a+b)</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/search.cgi?pdb=2ptk;ver=1.75</SCOP_URL>
    <CATH_Class>Mixed alpha-beta</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/2oiq</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Detail>site,338,Thr;site,340,Tyr;site,310,Glu;site,295,Lys;site,341,Met;range,404,406,DFG motif</Site_Detail>
      <Site_Reference>Getlik M, et al. J Med Chem.2009,52(13):3915-3926.</Site_Reference>
      <Site_Type>Molecular rearrangement</Site_Type>
      <PDB_ID>3F3V;3F3W;3G5D;3F3T;3F3U;2OIQ</PDB_ID>
      <PubMed_ID>19462975</PubMed_ID>
    </AllostericSite>
  </AllostericSite_List>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>2.7.10.2</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/7/10/2.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD00740001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00740002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00740003</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00740004</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00740005</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00740006</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00740007</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00740008</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00740009</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00740010</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00740011</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00740014</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00740015</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00740016</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00740017</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00740018</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00740019</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00740020</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00740024</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00740025</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00740027</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00740028</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD00740029</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD09800002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-05-31</Create_Date>
</Organism_Record>